In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.
about
Comparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and LidocaineA Mathematical Model of Neonatal Rat Atrial Monolayers with Constitutively Active Acetylcholine-Mediated K+ CurrentMathematical approaches to understanding and imaging atrial fibrillation: significance for mechanisms and managementPharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.The virtual heart as a platform for screening drug cardiotoxicity.The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysisComputational approaches to understand cardiac electrophysiology and arrhythmias.Human atrial fibrillation: insights from computational electrophysiological models.Novel ion channel targets in atrial fibrillation.Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.Na(+) current expression in human atrial myofibroblasts: identity and functional roles.Atrial-selective targeting of arrhythmogenic phase-3 early afterdepolarizations in human myocytesRevealing kinetics and state-dependent binding properties of IKur-targeting drugs that maximize atrial fibrillation selectivity.Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin.Modulation of late sodium current by Ca2+ -calmodulin-dependent protein kinase II, protein kinase C and Ca2+ during hypoxia in rabbit ventricular myocytes.Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future Challenges
P2860
Q28548133-DC783E3B-A0B8-401A-A6E1-87BF3F990C0AQ28552038-0C1D4243-E7AD-4AD8-AC45-AC95C23D0200Q30579851-7D42477A-CD2B-43A3-AA60-BE5CC29A1B5EQ34482842-E6D885E6-8509-4CD5-8108-E037CFF2BFBBQ36342116-FAAF910D-0A60-4185-A612-CB3614E51A04Q36650575-65A34908-7DD2-4C4F-84E6-5E1A6B469A98Q37174582-12658045-F6DD-4FB8-877E-0E94CF1FE9CBQ38021612-B206E0F2-D1DC-4780-95BF-FA4A98E82DCAQ38751315-99D99638-EA68-4CCA-9C1D-33FE30B64B4CQ38822819-DA9E99D8-61D3-45AB-AF82-5973252E65FBQ42102092-DB05D111-3842-4A3E-855D-2924E7BA4947Q42540023-47D1F6E3-5EBE-494C-9953-EB4E3814EBC9Q42694191-2A73D939-3166-4D41-B914-821755B7F3A4Q47161197-03ECE600-BA32-45F7-B02C-9D827F9B7D86Q48242012-8D43A911-3677-436E-AC0B-CB12A0DF43ACQ57161239-B16CA175-6DFC-44A1-95A4-DF530C0C2AC5
P2860
In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
In silico optimization of atri ...... nnel blocker pharmacodynamics.
@en
In silico optimization of atri ...... nnel blocker pharmacodynamics.
@nl
type
label
In silico optimization of atri ...... nnel blocker pharmacodynamics.
@en
In silico optimization of atri ...... nnel blocker pharmacodynamics.
@nl
prefLabel
In silico optimization of atri ...... nnel blocker pharmacodynamics.
@en
In silico optimization of atri ...... nnel blocker pharmacodynamics.
@nl
P2093
P2860
P1433
P1476
In silico optimization of atri ...... nnel blocker pharmacodynamics.
@en
P2093
Edward J Vigmond
Martin Aguilar-Shardonofsky
Philippe Comtois
P2860
P304
P356
10.1016/J.BPJ.2012.01.032
P407
P577
2012-03-06T00:00:00Z